Chung-Wang Ko
Overview
Explore the profile of Chung-Wang Ko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng H, Shiu S, Ko C
BMC Gastroenterol
. 2024 May;
24(1):152.
PMID: 38698314
Background And Aim: Esophageal squamous cell neoplasia (ESCN) is predominant in Asia. Endoscopic mucosal resection and endoscopic submucosal dissection (ESD) have both been recommended worldwide, however the application of endoscopic...
2.
Chuang T, Ko C, Shiu S
Medicine (Baltimore)
. 2023 Oct;
102(40):e35147.
PMID: 37800801
Background: Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease worldwide with decreased life expectancy. Duodenal mucosal resurfacing (DMR) has been associated...
3.
Che C, Shiu S, Ko C, Tu Y, Chang C
Dig Dis Sci
. 2023 Jul;
68(9):3534-3541.
PMID: 37490152
Background: Endoscopic band ligation (EBL) and radiofrequency ablation (RFA) have emerged as alternative therapies of gastric antral vascular ectasia (GAVE) in addition to endoscopic thermal therapy (ETT), but the optimum...
4.
Lee S, Peng Y, Lien H, Ko C, Tung C, Chang C
World J Clin Cases
. 2022 Sep;
10(21):7275-7284.
PMID: 36157996
Background: Transarterial chemoembolization (TACE) is a recommended treatment for patients with intermediate stage hepatocellular carcinoma (HCC) but with variable treatment outcomes. Aim: To determine factors for predicting outcomes of TACE...
5.
Lin Y, Liao S, Chang C, Chen C, Lin W, Chiu F, et al.
BMC Gastroenterol
. 2022 Jun;
22(1):309.
PMID: 35751028
Background: Cecal ulcers are sometimes encountered in asymptomatic individuals. Their clinical outcomes and management recommendations remain uncertain. Methods: Asymptomatic patients who underwent a colonoscopic exam for colon cancer screening were...
6.
Shiu S, Chang C, Tu Y, Ko C
Medicine (Baltimore)
. 2022 Jun;
101(24):e29441.
PMID: 35713453
Background: : Current guidelines recommend per-oral endoscopic myotomy (POEM) and laparoscopic Heller's myotomy (LHM) as first-line treatment of idiopathic achalasia, but the optimum choice between different endoscopic and surgical modalities...
7.
Lee S, Yang S, Lien H, Peng Y, Ko C, Lee T
J Clin Med
. 2022 Mar;
11(5).
PMID: 35268535
Aim: Currently, atezolizumab combined with bevacizumab is the standard first-line treatment for unresectable hepatocellular carcinoma (HCC), but lenvatinib or sorafenib are still recommended for these patients for some reasons. The...
8.
Tsai H, Tai J, Chen L, Wu M, Yeh K, Lin C, et al.
Haematologica
. 2019 Nov;
105(7):e349-e354.
PMID: 31727764
No abstract available.
9.
Lee S, Lien H, Chang C, Lin M, Chang C, Ko C
World J Clin Cases
. 2018 Dec;
6(14):753-758.
PMID: 30510939
Aim: To investigate the benefits of the Seattle protocol in the diagnosis of Chinese individuals with Barrett's esophagus. Methods: Subjects enrolled were patients from one center with endoscopically-suspected esophageal metaplasia....
10.
Lee S, Lien H, Peng Y, Lin M, Ko C, Chang C
JGH Open
. 2018 Nov;
2(5):214-216.
PMID: 30483592
Aim: The aim of this study was to investigate the incidence of dysplastic transformation of Barrett's esophagus (BE) in a Chinese population. Method: Data from nondysplastic BE patients at Taichung...